(Q35577484)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

review article

1 reference

title

Waldenström macroglobulinaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

2

Morie A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1

Irene M Ghobrial

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

679-685

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia - a new syndrome?

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Origins of the malignant clone in typical Waldenstrom's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Familial Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinemia: clinical features, complications, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

The spectrum of IgM monoclonal gammopathy in 430 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinaemia: laboratory diagnosis and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

The lung and Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Neuropathies associated with paraproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Hyperviscosity syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Immunophenotypic analysis of Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

IgM myeloma: different features from multiple myeloma and macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Amyloidosis with IgM monoclonal gammopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinemia: long-term results with the M-2 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Fludarabine therapy in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Treatment of Waldenström's macroglobulinemia with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Treatment of Waldenstrom's macroglobulinemia with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Transplantation in Waldenstrom's macroglobulinemia—the French experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Plasmapheresis in hyperviscosity syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Fludarabine therapy in Waldenström's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Fludarabine treatment in resistant Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901246-4

7 January 2021

10.1016/S1470-2045(03)01246-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14602248%20AND%20SRC:MED&resulttype=core&format=json

release_yt3n2mtxj5dvbjiawexzkkfpse

20 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yt3n2mtxj5dvbjiawexzkkfpse

24 November 2022

mapped directly with Wikidata item

1 reference